Back to news

Smithson Inv.Trust - Directorate Changes

Back to news
RNS Number : 6459B
Smithson Investment Trust PLC
15 February 2022

Smithson Investment Trust plc

Directorate Changes

The Board of Smithson Investment Trust plc (the "Company") announces that Mark Pacitti will retire from the Board on 28 February 2022. Diana Dyer Bartlett will become Chair of the Board and Lord St John of Bletso will replace Diana as Chair of the Audit Committee.

In addition, the Board announces the appointment of Jeremy Attard-Manche as a Director with effect from 1 March 2022. He will become Chair of the Management Engagement Committee, replacing Lord St John of Bletso.

Mr Attard-Manche is a former CEO of value equity hedge fund, Noster Capital LLP.  Directly prior to this, he was a partner at Tell Investments, which he jointly founded in 2002.  Previously, he was a Managing Director with Merrill Lynch in London, responsible for all hedge fund distribution in Europe.

Mr Attard-Manche holds no shares in the Company. There is no information to be disclosed in respect of paragraphs 9.6.13(2) to 9.6.13(6) of the FCA's Listing Rules.

Mrs Dyer Bartlett commented:

"On behalf of the Board, I would like to thank Mark for the contribution he has made as Chairman to the success of the Company since its IPO in October 2018."

For further information please contact:

Sanne Fund Services (UK) Limited                           +44 (0) 20 3327 9720

Company Secretary

LEI Number:52990070BDK2OKX5TH79

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
BOAZZGMZNDGGZZM